Earlier this week, we featured a presenting company for our upcoming BIO Investor Forum event in San Francisco in our ‘company snapshot‘ feature. For our next post, we spoke to MAX BioPharma, who will be giving a presentation in our Discovery Company presentation track, which features companies in their Seed or Series A financing rounds, with under 25 million raised to date. Read on to learn more about this Discovery Company.
What is your company’s lead product or technology?
MAX BioPharma’s lead product under development, Oxy133, is an osteoinductive small molecule oxysterol that induces robust bone formation upon localized administration in rat and rabbit spine fusion models. It is also effective in regenerating bone in rabbit cranial defect and rat femoral defect models. Our lead candidate small molecule oxysterol is inexpensive to make and will have a favorable safety profile.
How does your company go about differentiating itself from the competition?
MAX BioPharma’s proprietary small molecule osteoinductive oxysterol is a candidate for development into the next bone regenerating therapeutic agent. It works through the unique Hedgehog cell signaling pathway in mesenchymal stem cells that triggers osteogenic differentiation. In contrast to few other agents under pre-clincial development, our lead compound causes robust osteoinductive effects comparable to rhBMP2. In contrast to recombinant proteins, oxysterols are inexpensive to manufacture and have a favorable safety profile. It is a member of a larger family of small molecule oxysterols that regulate Hedgehog signaling that can be developed to target a variety of human indications.
What are the upcoming milestones and long-term priorities for your company?
MAX BioPharma aims to complete its pre-clinical tests in order to file an IDE with the FDA in the next 18-24 months to begin Phase I clinical trials for spine fusion. To accomplish this, we are raising am $8M Series A financing. Working with our FDA regulatory advisors, we are preparing for a pre-submission meeting with the FDA in the next few months.
Long-term, MAX BioPharma hopes to develop its proprietary small molecules for systemic administration in indications such as osteoporosis by targeting the Hedgehog signaling pathway in a bone selective manner, and various human cancers including pancreatic cancer.
Tell us something about your company that investors might not now.
MAX BioPharma is a pioneer in developing proprietary small molecule oxysterols that either positively or negatively regulate Hedgehog signaling for regenerative medicine or targeting human tumors, respectively. We have a robust platform technology and have secured an exclusive license agreement with UCLA for their rights.
See MAX BioPharma in the Discovery Company Track at the BIO Investor Forum, and look them up in our BIO One-on-One Partnering System to schedule meetings! Early Bird Registration Rates for the event expire next Thursday, August 22nd.
*Company snapshots are meant to be previews of presentations given at BIO events by way of answering set questions. BIO does not substantiate or validate any claims mentioned in company snapshots or presentations.